Hualei Gan

1.5k total citations
47 papers, 643 citations indexed

About

Hualei Gan is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Hualei Gan has authored 47 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pulmonary and Respiratory Medicine, 16 papers in Molecular Biology and 15 papers in Oncology. Recurrent topics in Hualei Gan's work include Prostate Cancer Treatment and Research (21 papers), Prostate Cancer Diagnosis and Treatment (14 papers) and Renal cell carcinoma treatment (9 papers). Hualei Gan is often cited by papers focused on Prostate Cancer Treatment and Research (21 papers), Prostate Cancer Diagnosis and Treatment (14 papers) and Renal cell carcinoma treatment (9 papers). Hualei Gan collaborates with scholars based in China, United States and Austria. Hualei Gan's co-authors include Yao Zhu, Junlong Wu, Dingwei Ye, Wei Yu, Yijun Shen, Bo Dai, Weijie Gu, Xiaojian Qin, Guohai Shi and Jian Pan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.

In The Last Decade

Hualei Gan

47 papers receiving 640 citations

Peers

Hualei Gan
J. Garcia United States
JuanJuan Yin United States
Milan Mangeshkar United States
Natalie Vena United States
A. Kooistra Netherlands
J. Garcia United States
Hualei Gan
Citations per year, relative to Hualei Gan Hualei Gan (= 1×) peers J. Garcia

Countries citing papers authored by Hualei Gan

Since Specialization
Citations

This map shows the geographic impact of Hualei Gan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hualei Gan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hualei Gan more than expected).

Fields of papers citing papers by Hualei Gan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hualei Gan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hualei Gan. The network helps show where Hualei Gan may publish in the future.

Co-authorship network of co-authors of Hualei Gan

This figure shows the co-authorship network connecting the top 25 collaborators of Hualei Gan. A scholar is included among the top collaborators of Hualei Gan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hualei Gan. Hualei Gan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Wei, Hualei Gan, Xiaomeng Li, et al.. (2025). Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study. Cell Reports Medicine. 6(3). 102018–102018. 3 indexed citations
2.
Pan, Jian, Junlong Wu, Bin Zhu, et al.. (2024). Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer. Med. 5(12). 1475–1484.e3. 5 indexed citations
3.
Zhao, Ming, Xiaoqun Yang, Hualei Gan, et al.. (2024). ALK-Rearranged Renal Cell Carcinoma: A Multi-Institutional Study of 9 Cases With Expanding the Morphologic and Molecular Genetic Spectrum. Modern Pathology. 37(8). 100536–100536. 5 indexed citations
4.
6.
Yu, Wei, Jian Pan, Shengming Jin, et al.. (2023). Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity. Molecular Oncology. 17(10). 2183–2199. 6 indexed citations
7.
Yu, Pengcheng, Ning Qu, Rui Zhu, et al.. (2023). TERT accelerates BRAF mutant–induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. Science Advances. 9(35). eadg7125–eadg7125. 39 indexed citations
8.
Wang, Yue, Xi Tian, Wenhao Xu, et al.. (2023). Identification of prognostic and therapeutic biomarkers in type 2 papillary renal cell carcinoma. World Journal of Surgical Oncology. 21(1). 98–98. 2 indexed citations
9.
Yu, Wei, Hao Zeng, Yonghong Li, et al.. (2022). Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients. Cancer Immunology Immunotherapy. 72(6). 1541–1551. 11 indexed citations
11.
Pan, Jian, Hualei Gan, Wei Yu, et al.. (2022). The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer. Molecular Oncology. 16(22). 4011–4022. 10 indexed citations
12.
Jin, Shengming, Junjie Wang, Junlong Wu, et al.. (2020). Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective Study. Frontiers in Oncology. 10. 527952–527952. 4 indexed citations
13.
Yu, Wei, Junlong Wu, Weijie Gu, et al.. (2019). Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients. European Urology. 76(3). 280–283. 43 indexed citations
14.
Bi, Rui, Qianming Bai, Xiaoli Zhu, et al.. (2019). ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma. Diagnostic Pathology. 14(1). 96–96. 11 indexed citations
15.
Jin, Shengming, Junjie Wang, Yijun Shen, et al.. (2019). Comparison of different lymph node staging schemes in prostate cancer patients with lymph node metastasis. International Urology and Nephrology. 52(1). 87–95. 6 indexed citations
16.
Ma, Jian, Kun Chang, Jingtao Peng, et al.. (2018). SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression. Journal of Experimental & Clinical Cancer Research. 37(1). 145–145. 46 indexed citations
17.
Wang, Qifeng, Hualei Gan, Yifeng Sun, et al.. (2017). Identification and validation of a 44-gene expression signature for the classification of renal cell carcinomas. Journal of Experimental & Clinical Cancer Research. 36(1). 176–176. 12 indexed citations
18.
Xu, Fujiang, Kun Chang, Jian Ma, et al.. (2017). The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma. Scientific Reports. 7(1). 9846–9846. 25 indexed citations
19.
Yang, Xiaoqun, et al.. (2015). [Primary osteosarcoma of kidney: report of a case].. PubMed. 44(6). 412–3. 1 indexed citations
20.
Ye, Dingwei, Kun Chang, Bo Dai, et al.. (2014). Genitourinary small-cell carcinoma: 11-year treatment experience. Asian Journal of Andrology. 16(5). 705–705. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026